TP53 and acute myeloid leukemia: In summary, this study provides strong preclinical evidence supporting that a novel strategy combining TPL and ABT-199 markedly induces apoptosis of AML cells regardless of their p53 status and thereby displays the markedly improved efficacy towards AML in vitro and in vivo.